

**Remarks**

Claims 1-4, 7-11, 30, 31, 34-36, 42, 43, 49, 55, 59, 64, 65, 69, 72 and 73 are pending in the application. Applicants would like to apologize for the confusion relating to previously cancelled Claims 61-63, 66-68, and 70-71. As requested by the Examiner, a new set of claims with the proper designations have been submitted herewith.

Although Applicants maintain that Claims 60, 65, 69, 72 and 73 fulfill the requirements of §112, 1<sup>st</sup> and 2<sup>nd</sup> paragraphs as argued in the previous amendments, these claims have been cancelled to expedite the application to allowance. Consequently, all outstanding rejections have been rendered moot.

Respectfully Submitted:

Date:

November 8, 2006

Arlene K. Musser

Arlene K. Musser  
Attorney for Applicants  
Registration No. 37,895

Pfizer Inc.  
Patent Department, MS: 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871